BioCryst Pharmaceuticals | 销售成本

金融业

USD

USD 446.42M

现金及等价物

USD 84.08M

USD 12.27M

USD 355.68M

USD 190.24M

USD 828.6M

股息收益率

0

USD -4.51M

USD -20.3M

536

EPS每股收益

USD -0.13

股本和储备

USD -387.89M

USD -88.88M

债务利息支出

USD 24.45M

USD -0.13

USD 194.37M

USD 1.3B

USD -88.88M

USD -387.89M

USD -2.54M

普通股股本

USD 1.9M

1.08K

USD -86.95M

USD -86.95M

销售和管理费用

USD 80.47M

USD 5.23M

贸易债权人

USD 5.57M

应收帐款人

USD 79.07M

	销售成本	更改		日
Alnylam Pharmaceuticals	USD 200.15M		57.2M	2025-09
BioCryst Pharmaceuticals	USD 12.27M		9.04M	2024-12
Chugai Pharma	JPY 87.56B		12.68B	2025-12
Daiichi Sankyo	JPY 118.28B		37.7B	2025-12
Gilead Sciences	USD 1.57B		68M	2025-09
GlaxoSmithKline	GBP 2.61B		377M	2025-12
Glaxosmithkline	GBP 3.01B		853.01M	2025-09
Incyte	USD 121.18M		22.18M	2025-12
Ionis Pharmaceuticals	USD 2.34M		1.81M	2025-09
Karyopharm Therapeutics	USD 37.43M		2.41M	2024-09
Neurocrine Biosciences	USD 264M		252.7M	2025-09
Novavax	USD 60.62M		91.77M	2024-09
PTC Therapeutics	USD 23.32M		7.83M	2025-09
Regeneron Pharmaceuticals	USD 584.6M		63M	2025-12
Roche Holding	CHF 8.48B		4.61B	2025-12
Sarepta Therapeutics	USD 151.45M		1.77M	2025-09
Ultragenyx Pharmaceutical	USD 27.99M		4.99M	2025-09
Vertex Pharmaceuticals	USD 414.8M		7.3M	2025-09

BioCryst Pharmaceuticals 销售成本 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.